Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 21

1.

Serum vitamin D levels are not predictive of the progression of chronic liver disease in hepatitis C patients with advanced fibrosis.

Corey KE, Zheng H, Mendez-Navarro J, Delgado-Borrego A, Dienstag JL, Chung RT; HALT-C Trial Group.

PLoS One. 2012;7(2):e27144. doi: 10.1371/journal.pone.0027144. Epub 2012 Feb 16.

2.

Predicting clinical outcomes using baseline and follow-up laboratory data from the hepatitis C long-term treatment against cirrhosis trial.

Ghany MG, Kim HY, Stoddard A, Wright EC, Seeff LB, Lok AS; HALT-C Trial Group.

Hepatology. 2011 Nov;54(5):1527-37. doi: 10.1002/hep.24550.

3.

Predicting cirrhosis and clinical outcomes in patients with advanced chronic hepatitis C with a panel of genetic markers (CRS7).

Curto TM, Lagier RJ, Lok AS, Everhart JE, Rowland CM, Sninsky JJ; HALT-C Trial group.

Pharmacogenet Genomics. 2011 Dec;21(12):851-60. doi: 10.1097/FPC.0b013e32834c3e74.

4.

Extended interferon-alpha therapy accelerates telomere length loss in human peripheral blood T lymphocytes.

O'Bryan JM, Potts JA, Bonkovsky HL, Mathew A, Rothman AL; HALT-C Trial Group.

PLoS One. 2011;6(8):e20922. doi: 10.1371/journal.pone.0020922. Epub 2011 Aug 4.

5.

An IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C.

O'Brien TR, Everhart JE, Morgan TR, Lok AS, Chung RT, Shao Y, Shiffman ML, Dotrang M, Sninsky JJ, Bonkovsky HL, Pfeiffer RM; HALT-C Trial Group.

PLoS One. 2011;6(7):e20904. doi: 10.1371/journal.pone.0020904. Epub 2011 Jul 8.

6.

A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C.

Dienstag JL, Ghany MG, Morgan TR, Di Bisceglie AM, Bonkovsky HL, Kim HY, Seeff LB, Szabo G, Wright EC, Sterling RK, Everson GT, Lindsay KL, Lee WM, Lok AS, Morishima C, Stoddard AM, Everhart JE; HALT-C Trial Group.

Hepatology. 2011 Aug;54(2):396-405. doi: 10.1002/hep.24370. Epub 2011 Jun 23.

7.

Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon.

Di Bisceglie AM, Stoddard AM, Dienstag JL, Shiffman ML, Seeff LB, Bonkovsky HL, Morishima C, Wright EC, Snow KK, Lee WM, Fontana RJ, Morgan TR, Ghany MG; HALT-C Trial Group.

Hepatology. 2011 Apr;53(4):1100-8. doi: 10.1002/hep.24169.

8.

A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma.

Abu Dayyeh BK, Yang M, Fuchs BC, Karl DL, Yamada S, Sninsky JJ, O'Brien TR, Dienstag JL, Tanabe KK, Chung RT; HALT-C Trial Group.

Gastroenterology. 2011 Jul;141(1):141-9. doi: 10.1053/j.gastro.2011.03.045. Epub 2011 Mar 24.

9.

Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C.

Freedman ND, Curto TM, Lindsay KL, Wright EC, Sinha R, Everhart JE; HALT-C TRIAL GROUP.

Gastroenterology. 2011 Jun;140(7):1961-9. doi: 10.1053/j.gastro.2011.02.061. Epub 2011 Mar 2.

10.

Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C.

Lok AS, Everhart JE, Di Bisceglie AM, Kim HY, Hussain M, Morgan TR; HALT-C Trial Group.

Hepatology. 2011 Aug;54(2):434-42. doi: 10.1002/hep.24257.

11.

Iron levels in hepatocytes and portal tract cells predict progression and outcomes of patients with advanced chronic hepatitis C.

Lambrecht RW, Sterling RK, Naishadham D, Stoddard AM, Rogers T, Morishima C, Morgan TR, Bonkovsky HL; HALT-C Trial Group.

Gastroenterology. 2011 May;140(5):1490-500.e3. doi: 10.1053/j.gastro.2011.01.053. Epub 2011 Feb 15.

12.

No increase in depression with low-dose maintenance peginterferon in prior non-responders with chronic hepatitis C.

Kronfol Z, Litman HJ, Back-Madruga C, Bieliauskas LA, Lindsay KL, Lok AS, Fontana RJ; HALT-C Trial Group.

J Affect Disord. 2011 Mar;129(1-3):205-12. doi: 10.1016/j.jad.2010.09.010.

13.

Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C.

Fontana RJ, Dienstag JL, Bonkovsky HL, Sterling RK, Naishadham D, Goodman ZD, Lok AS, Wright EC, Su GL; HALT-C Trial Group.

Gut. 2010 Oct;59(10):1401-9. doi: 10.1136/gut.2010.207423. Epub 2010 Jul 30.

14.

A functional serotonin transporter gene polymorphism and depressive effects associated with interferon-alpha treatment.

Pierucci-Lagha A, Covault J, Bonkovsky HL, Feinn R, Abreu C, Sterling RK, Fontana RJ, Kranzler HR; HALT-C Trial Group.

Psychosomatics. 2010 Mar-Apr;51(2):137-48. doi: 10.1176/appi.psy.51.2.137.

15.

Automated summaries of serious adverse events in the hepatitis C antiviral long-term treatment against cirrhosis trial.

Bell MC, Robuck PR, Wright EC, Mihova MS, Hofmann C, De Santo JL, Milstein SL, Richtmyer PA, Shelton JL, Cormier M, King DL, Park CJ, Molchen WA, Park Y, Kelley M.

Clin Trials. 2009 Dec;6(6):618-27. doi: 10.1177/1740774509348525. Epub 2009 Nov 4.

16.

Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C.

Freedman ND, Everhart JE, Lindsay KL, Ghany MG, Curto TM, Shiffman ML, Lee WM, Lok AS, Di Bisceglie AM, Bonkovsky HL, Hoefs JC, Dienstag JL, Morishima C, Abnet CC, Sinha R; HALT-C Trial Group.

Hepatology. 2009 Nov;50(5):1360-9. doi: 10.1002/hep.23162.

17.

Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial.

Welzel TM, Morgan TR, Bonkovsky HL, Naishadham D, Pfeiffer RM, Wright EC, Hutchinson AA, Crenshaw AT, Bashirova A, Carrington M, Dotrang M, Sterling RK, Lindsay KL, Fontana RJ, Lee WM, Di Bisceglie AM, Ghany MG, Gretch DR, Chanock SJ, Chung RT, O'Brien TR; HALT-C Trial Group.

Hepatology. 2009 Jun;49(6):1847-58. doi: 10.1002/hep.22877.

18.

Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial.

Lok AS, Everhart JE, Chung RT, Kim HY, Everson GT, Hoefs JC, Greenson JK, Sterling RK, Lindsay KL, Lee WM, Di Bisceglie AM, Bonkovsky HL, Ghany MG, Morishima C; HALT-C Trial Group.

Hepatology. 2009 Jun;49(6):1828-37. doi: 10.1002/hep.22865.

19.

Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis.

Fontana RJ, Bonkovsky HL, Naishadham D, Dienstag JL, Sterling RK, Lok AS, Su GL; Halt-C Trial Group.

Clin Gastroenterol Hepatol. 2009 Feb;7(2):219-26. doi: 10.1016/j.cgh.2008.10.034. Epub 2008 Nov 7.

20.

Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon.

Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, Lee WM, Lok AS, Bonkovsky HL, Morgan TR, Ghany MG, Morishima C, Snow KK, Dienstag JL; HALT-C Trial Investigators.

N Engl J Med. 2008 Dec 4;359(23):2429-41. doi: 10.1056/NEJMoa0707615.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk